Core Viewpoint - COSCIENS Biopharma Inc. has decided to cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, leading to an anticipated structured insolvency process for these entities [1][2]. Company Strategy - The company has historically focused on developing its pharmaceutical assets, particularly Macrilen (macimorelin), through its German subsidiaries, which have operated at a loss [2]. - The long-term viability of the biopharmaceutical business has depended on expanding the market for Macrilen, especially through obtaining FDA approval for a pediatric indication in the U.S. [2]. - Following disappointing results from Macrilen's Phase 3 DETECT trial and a subsequent meeting with the FDA, the company is exploring various strategic options, including potential sales of the product or subsidiaries and additional licensing opportunities [2]. Financial Implications - The expected insolvency process will result in the company surrendering its rights to Macrilen and significantly reducing ongoing operating expenses [3]. - The decision to stop funding the German subsidiaries is viewed as a necessary step towards achieving profitability for the company [3]. Future Focus - Moving forward, the company will concentrate on maximizing profitability from its active ingredients business and evaluating other opportunities [3][4].
COSCIENS Provides Strategic Update